Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Anas Younes(Intercept Pharmaceuticals (United States)), Andreas Engert(University of Cologne), Patrick B. Johnston(Mayo Clinic in Arizona), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Simon J. Harrison(Peter MacCallum Cancer Centre), Jennifer Gallagher(City Of Hope National Medical Center), Angela Shen(Unknown), Tee-Chuan Ong(City Of Hope National Medical Center), Dina Ben‐Yehuda(Hebrew University of Jerusalem), H. Miles Prince(Peter MacCallum Cancer Centre), Christophe Le Corre(City Of Hope National Medical Center), Mark Kirschbaum(Cyclacel Pharmaceuticals (United States))
Cited by 261
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657